A
Aligos Therapeutics
Aligos is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
About Aligos Therapeutics
Aligos Therapeutics is a biopharmaceutical company focused on developing targeted therapies for chronic liver diseases and viral infections. The company leverages its expertise in small molecule and oligonucleotide platforms to create drug candidates with clinically validated targets and optimized pharmacological characteristics. Aligos aims to address unmet medical needs in conditions such as chronic hepatitis B (CHB), COVID-19, and Nonalcoholic Steatohepatitis (NASH). The company operates in the biopharmaceutical market, primarily serving healthcare providers and patients affected by these diseases. Aligos generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
News
Open roles
Aligos Therapeutics in the San Francisco ecosystem
The Aligos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aligos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aligos Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



